FDA accepts Larotrectinib New Drug Application and Grants Priority Review
The FDA has accepted the NDA and granted Priority Review for larotrectinib for advanced or metastatic solid tumours harbouring a NTRK gene fusion...
List view / Grid view
The FDA has accepted the NDA and granted Priority Review for larotrectinib for advanced or metastatic solid tumours harbouring a NTRK gene fusion...